EU/3/14/1356: Orphan designation for the treatment of acute myeloid leukaemia
Donor T lymphocytes depleted ex-vivo of host alloreactive T cells using photodynamic treatment
Table of contents
Overview
On 19 November 2014, orphan designation (EU/3/14/1356) was granted by the European Commission to Kiadis Pharma Netherlands B.V., the Netherlands, for donor T lymphocytes depleted ex-vivo of host alloreactive T cells using photodynamic treatment for the treatment of acute myeloid leukaemia.
Please note that this product was withdrawn from the Union Register of orphan medicinal products in February 2022 on request of the Sponsor.
Key facts
Active substance |
Donor T lymphocytes depleted ex-vivo of host alloreactive T cells using photodynamic treatment
|
Intended use |
Treatment of acute myeloid leukaemia
|
Orphan designation status |
Withdrawn
|
EU designation number |
EU/3/14/1356
|
Date of designation |
19/11/2014
|
Sponsor |
Kiadis Pharma Netherlands B.V
Entrada 231-234 1114 AA Amsterdam-Duivendrecht The Netherlands Tel. +31 20 314 0250 Fax +31 20 314 0251 E-mail: info@kiadis.com |
Review of designation
The Committee for Orphan Medicinal Products reviews the orphan designation of a product if it is approved for marketing authorisation.
Patients' organisations
For contact details of patients’ organisations whose activities are targeted at rare diseases, see:
European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.
Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.
EU register of orphan medicines
The list of medicines that have received an orphan designation in the EU is available on the European Commission's website: